読み込み中
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
前日終値
$2.78
+$0.085 · +3.15%
日中の時刻はETです。市場データは遅延する場合があります。
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
日中レンジ
現在 $2.78
52週レンジ
現在 $2.78
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
81
大幅な割安
センチメント
62
強気
リスク
41
やや高いリスク
モメンタム
57
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
日中レンジ
現在 $2.78
52週レンジ
現在 $2.78
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 5274.4万 USD | 5339.9万 USD | 6549.4万 USD | 4763.8万 USD | 3835万 USD |
| 売上原価 | 2750.8万 USD | 2431.9万 USD | 2298.2万 USD | 1959.2万 USD | 1634.9万 USD |
| 粗利益 | 2523.6万 USD | 2908万 USD | 4251.2万 USD | 2804.6万 USD | 2200.1万 USD |
| 研究開発 | 1905.4万 USD | 1297万 USD | 1709.3万 USD | 2934.9万 USD | 2973.4万 USD |
| 販売・一般管理 | 1168.2万 USD | 1219.3万 USD | 1495.9万 USD | 1171.1万 USD | 1272.9万 USD |
| 営業費用 | 3073.6万 USD | 2516.3万 USD | 3205.2万 USD | 4106万 USD | 4246.3万 USD |
| 受取利息 | 108.3万 USD | 129.9万 USD | 128.6万 USD | 114.6万 USD | 40.1万 USD |
| 支払利息 | 119.1万 USD | 106.2万 USD | 318万 USD | 252.9万 USD | 752.1万 USD |
| 減価償却費と償却費 | 146.5万 USD | 130.4万 USD | 119.1万 USD | 108.6万 USD | 111.8万 USD |
| 営業利益 | −550万 USD | 391.7万 USD | 1046万 USD | −1301.4万 USD | −2046.2万 USD |
| 純利益 | −660.4万 USD | 293.2万 USD | 831.2万 USD | −1492.7万 USD | −2758.2万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
| 種別 | 発効日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
株式分割 | 2019年12月20日 | 1:10 | — | — |
株式分割 | 2007年1月3日 | 1:10 | — | — |
発効済み 2019年12月20日
1:10
発効済み 2007年1月3日
1:10
この株式へのエクスポージャーを報告している上場投資信託です。
iShares Russell 2000 ETFIWM533.29万0.01%787.4億 USD0.19%$278.94+0.49%
Schwab International Small-Cap Equity ETFSCHC244.54万0.04%55.33億 USD0.06%$49.47+0.84%
iShares Russell 2000 Growth ETFIWO201.18万0.01%139.17億 USD0.24%$356.78+0.94%
State Street SPDR Portfolio Developed World ex-US ETFSPDW196.2万0.00%404.62億 USD0.03%$49.98+0.64%
Vanguard Russell 2000 ETFVTWO108.99万0.01%180億 USD0.06%$112.66+0.50%
iShares Micro-Cap ETFIWC68.47万0.05%13.17億 USD0.60%$183+0.11%
Dimensional - US Small Cap ETFDFAS67.84万0.00%338.69億 USD0.31%$78.35+0.32%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM27万0.23%1.17億 USD0.73%$15.9402+0.25%iShares Russell 2000 ETFIWMSchwab International Small-Cap Equity ETFSCHCiShares Russell 2000 Growth ETFIWOState Street SPDR Portfolio Developed World ex-US ETFSPDWVanguard Russell 2000 ETFVTWOiShares Micro-Cap ETFIWCDimensional - US Small Cap ETFDFASEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
